77 | Parkinson disease |
72 | Humans |
55 | Nervous system diseases |
44 | Male |
37 | Female |
34 | Aged |
31 | Human |
28 | Middle Aged |
24 | Animals |
17 | Parkinson's disease |
17 | Adult |
13 | Parkinson Disease (physiopathology) |
13 | Levodopa |
13 | Dyskinesia |
12 | Parkinson Disease (genetics) |
11 | Treatment |
11 | Parkinson Disease (drug therapy) |
10 | Parkinson Disease (diagnosis) |
10 | Parkinson Disease (complications) |
9 | Parkinson Disease (therapy) |
9 | Parkinson Disease (pathology) |
8 | Parkinson Disease (psychology) |
8 | Parkinson Disease (epidemiology) |
8 | Mutation |
8 | Mice |
8 | Dopamine |
8 | Brain (metabolism) |
8 | Aged, 80 and over |
7 | Review |
7 | Neuropsychological Tests |
7 | Basal ganglion |
6 | parkinsonism |
6 | Treatment Outcome |
6 | Severity of Illness Index |
6 | Pathogenesis |
6 | Parkinsonism |
6 | Parkinson Disease (metabolism) |
6 | Encephalon |
6 | Deep brain stimulation |
6 | Cohort Studies |
6 | Cognition |
6 | Antiparkinson agent |
5 | Subthalamic nucleus |
5 | Ropinirole |
5 | Phenotype |
5 | Mutation (genetics) |
5 | Mice, Inbred C57BL |
5 | Magnetic Resonance Imaging |
5 | Evaluation |
5 | Emission tomography |
5 | Electroencephalography |
5 | Diagnosis |
5 | Comparative study |
5 | Clinical management |
5 | Brain (pathology) |
5 | Animal |
5 | Animal model |
4 | multiple system atrophy |
4 | genetics |
4 | dystonia |
4 | dyskinesia |
4 | Ubiquitin-Protein Ligases (genetics) |
4 | Sequence Alignment |
4 | Risk Factors |
4 | Prevalence |
4 | Positron |
4 | Pedigree |
4 | Pathophysiology |
4 | Parkinson Disease (etiology) |
4 | Nuclear magnetic resonance imaging |
4 | Motor control |
4 | Molecular Sequence Data |
4 | Longitudinal Studies |
4 | Huntington disease |
4 | Genomics |
4 | Gene Expression Regulation |
4 | Elderly |
4 | Dopamine agonist |
4 | Disease Models, Animal |
4 | Degeneration |
4 | Deep Brain Stimulation (methods) |
4 | Decision making |
4 | D2 Dopamine receptor |
4 | Chemotherapy |
4 | Case-Control Studies |
4 | Amino Acid Sequence |
4 | Alzheimer disease |
4 | Age of Onset |
3 | rating scales |
3 | motor fluctuations |
3 | levodopa |
3 | clinimetrics |
3 | United States |
3 | Ubiquitin-Protein Ligases (metabolism) |
3 | Ubiquitin-Protein Ligases (chemistry) |
3 | Tremor |
3 | Time Factors |
3 | Surveys and Questionnaires |
3 | Speech |
3 | Spain |
3 | Sensorimotor cortex |
3 | Safety |
3 | Protein-Serine-Threonine Kinases (genetics) |
3 | Protein Conformation |
3 | Prognosis |
3 | Prediction |
3 | Parkinson Disease (diagnostic imaging) |
3 | Oscillation |
3 | Multiple system atrophy |
3 | Multiple System Atrophy (diagnosis) |
3 | Models, Molecular |
3 | Mitochondria (metabolism) |
3 | Lewy Body Disease (genetics) |
3 | Levodopa (therapeutic use) |
3 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
3 | Italy |
3 | Incidence |
3 | Genome-Wide Association Study |
3 | Genetics |
3 | Genetic disease |
3 | Genetic Association Studies |
3 | Functional imaging |
3 | Familial disease |
3 | Exploration |
3 | Emotions (physiology) |
3 | Electromyography |
3 | Dystonia |
3 | Double-Blind Method |
3 | Double blind study |
3 | Dopamine Agents (therapeutic use) |
3 | Dementia |
3 | Computational Biology |
3 | Cognition (physiology) |
3 | Canada |
3 | Brain (physiopathology) |
3 | Apolipoproteins E (genetics) |
3 | Antiparkinson Agents (therapeutic use) |
3 | Analysis of Variance |
3 | Agonist |
2 | tau Proteins (genetics) |
2 | specificity |
2 | sensitivity |
2 | progressive supranuclear palsy |
2 | prediction |
2 | mitochondria |
2 | methods: statistical |
2 | meta‐analysis |
2 | galaxies: dwarf |
2 | epidemiology |
2 | diagnostic criteria |
2 | deep brain stimulation |
2 | cosmic microwave background |
2 | classification |
2 | alpha-Synuclein (metabolism) |
2 | alpha-Synuclein (genetics) |
2 | Working memory |
2 | Woman |
2 | Virulence |
2 | Uptake |
2 | United Kingdom |
2 | Uncertainty |
2 | Ubiquitin (metabolism) |
2 | UPDRS |
2 | Transcranial magnetic stimulation |
2 | Toxoplasma (pathogenicity) |
2 | Toxoplasma (genetics) |
2 | Topiramate |
2 | Thalamus |
2 | Synteny |
2 | Symptomatology |
2 | Supranuclear ophthalmoplegia |
2 | Supranuclear Palsy, Progressive (diagnosis) |
2 | Stroke |
2 | Speech Perception (physiology) |
2 | Specificity |
2 | Single photon emission tomography |
2 | Sex Factors |
2 | Serotonin |
2 | Sequence Homology, Amino Acid |
2 | Sensitivity |
2 | Schizophrenia |
2 | Risk |
2 | Risk factor |
2 | Revision |
2 | Retrospective Studies |
2 | Reproducibility of Results |
2 | Rats |
2 | Rat |
2 | Radiopharmaceuticals |
2 | RNA, Messenger (genetics) |
2 | Quality of Life |
2 | Psychotropic |
2 | Psychiatric Status Rating Scales |
2 | Protozoan Proteins (genetics) |
2 | Prospective |
2 | Prospective Studies |
2 | Primates |
2 | Prefrontal cortex |
2 | Positron emission tomography |
2 | Polymorphism, Single Nucleotide |
2 | Plasticity |
2 | Piperidines (therapeutic use) |
2 | Phylogeny |
2 | Pedunculopontine Tegmental Nucleus (physiology) |
2 | Nootropic agent |
2 | Neuroimaging |
2 | Nervous System Diseases (diagnosis) |
2 | Myelodysplastic syndrome |
2 | Multiple System Atrophy (physiopathology) |
2 | Multicenter study |
2 | Mouse |
2 | Motor system disorder |
2 | Motor Cortex (physiology) |
2 | Monkey |
2 | Molecular Targeted Therapy |
2 | Models |
2 | Modeling |
2 | Mice, Transgenic |
2 | Mice, Knockout |
2 | Memory (physiology) |
2 | Medicine |
2 | Long term |
2 | Lewy body |
2 | Levodopa (pharmacology) |
2 | Levetiracetam |
2 | LRRK2 |
2 | Japan |
2 | Internet |
2 | Information processing |
2 | Impulse control disorder |
2 | Immunohistochemistry |
2 | Identification |
2 | Homeostasis |
2 | High-Throughput Screening Assays |
2 | Haplotypes |
2 | Glutamate |
2 | Genome, Protozoan |
2 | Genetic Variation |
2 | Genetic Predisposition to Disease |
2 | Genetic Predisposition to Disease (genetics) |
2 | Gene Expression Profiling |
2 | Galaxy: formation |
2 | Gait |
2 | Gait Disorders, Neurologic (etiology) |
2 | Functional Laterality (physiology) |
2 | France |
2 | Follow-Up Studies |
2 | Fluctuations |
2 | Facial Expression |
2 | Executive function |
2 | Excitability |
2 | Evaluation scale |
2 | Europe |
2 | Etiopathogenesis |
2 | Epidemiology |
2 | Emotion emotionality |
2 | Drug Delivery Systems |
2 | Dose-Response Relationship, Drug |
2 | Dopaminergic Neurons (metabolism) |
2 | Dopamine (metabolism) |
2 | Dopa |
2 | Dominant character |
2 | Disease Progression |
2 | Development |
2 | Dementia (complications) |
2 | Degenerative disease |
2 | Deep Brain Stimulation |
2 | Databases, Factual (statistics & numerical data) |
2 | Cues |
2 | Cross-Cultural Comparison |
2 | Corpus striatum |
2 | Conserved Sequence |
2 | Conserved Sequence (genetics) |
2 | Complication |
2 | Communication |
2 | Coherence |
2 | Cognition Disorders (etiology) |
2 | Coccidiosis (parasitology) |
2 | Clinical Trials as Topic |
2 | Cerebrovascular disease |
2 | Case study |
2 | Carrier Proteins (genetics) |
2 | Canada (epidemiology) |
2 | Blood flow |
2 | Behavior |
2 | Base Sequence |
2 | Axon |
2 | Autosomal character |
2 | Autopsy |
2 | Animal Experimentation (standards) |
2 | Aminoacid |
2 | Amantadine |
2 | Alzheimer Disease (genetics) |
2 | Alleles |
2 | Algorithms |
2 | Age Factors |
2 | AMPA receptor |
1 | ‘light/mild’ cigarettes |
1 | ‘light/mild’ beliefs |
1 | μm, Micrometers |
1 | β Amyloid protein |
1 | xenolith |
1 | white matter irregularities with increased signal on T2‐weighted images |
1 | wearing‐off |
1 | voluntary control |
1 | volar pads |
1 | vitamin D |
1 | visual hallucination |
1 | ventriculomegaly |
1 | ventricular tachycardia |
1 | ventricular fibrillation |
1 | venous sinus thrombosis |
1 | venous drainage congestion |
1 | validity |
1 | trunk flexion |
1 | trunk extension |
1 | tremor |
1 | treatment |
1 | translational |
1 | transfer function |
1 | tongue |
1 | titanite |
1 | time scales |
1 | tics |
1 | thickened corpus callosum |
1 | testate amoebae |
1 | taxonomy |
1 | tauopathies |
1 | tau Proteins (metabolism) |
1 | task force |
1 | systematic review |
1 | sustainability |
1 | surveys |
1 | subthalamic nucleus |
1 | substance abuse |
1 | stroke |
1 | spawning time |
1 | spatial analyses |
1 | smell |
1 | slow progression |
1 | sequencing |
1 | self‐injurious behavior |
1 | seasonal variation |
1 | safety |
1 | s, Seconds |
1 | ropinirole |
1 | reproductive potential |
1 | reporting recommendations |
1 | reliability |
1 | rehabilitation |
1 | reevaluation |
1 | recruitment |
1 | reciprocal altruism |
1 | recessive inheritance |
1 | rapidly growing cerebellum |
1 | quality of life |
1 | psychogenic movements |
1 | protein production |
1 | protein function prediction |
1 | protease inhibitors |
1 | prominent optic nerve sheaths |
1 | prominent Virchow–Robin spaces |
1 | progressive posterior fossa crowding |
1 | programming |
1 | primates |
1 | prevention |
1 | premutation |
1 | potassic magma |
1 | positron emission tomography |
1 | population structure |
1 | population genetics |
1 | polymicrogyria |
1 | polymerase gamma gene |
1 | phylogeography |
1 | phenotype |
1 | pharmacogenomics |
1 | peroxyl radical |
1 | peroxy radical |
1 | perampanel |
1 | peptide |
1 | peatlands |
1 | partial Mantel test |
1 | parameter |
1 | paralinguistic aspects of speech |
1 | palatal tremor |
1 | pain |
1 | p120RasGAP |
1 | oxidation |
1 | overt reading |
1 | orolingual |
1 | orobulbar features |
1 | opioids |
1 | onset age |
1 | olfaction |
1 | obstructive ventriculomegaly |
1 | nuclear receptors |
1 | non‐motor |
1 | neurotoxicity |
1 | neuroacanthocytosis |
1 | nerve growth factors |
1 | naloxone |
1 | nA, Nanoamp |
1 | myoclonus |
1 | motor complications |
1 | monazite |
1 | molecular systematics |
1 | mm, Millimeters |
1 | ml, Milliliters |
1 | mitochondrial disease |
1 | mitochondrial DNA |
1 | misleading terms |
1 | misconceptions |
1 | min, Minutes |
1 | microtubule‐associated protein tau |
1 | metamorphism |
1 | metal ion complexes |
1 | meningioma |
1 | mass‐media campaign |
1 | malformation |
1 | macrocyclic ligands |
1 | mV, Millivolts |
1 | mA, Milliamp |
1 | lava |
1 | late Quaternary |
1 | large‐scale structure of Universe |
1 | landscape genetics |
1 | labelling change |
1 | jaw |
1 | isodesmic reaction |
1 | introductions |
1 | intergalactic medium |
1 | intellectual disability |
1 | infrared: galaxies |
1 | information transfer |
1 | i.v., Intravenous |
1 | i.m., Intramuscular |
1 | homozygosity mapping |
1 | hexokinase |
1 | hereditary hemorrhagic telangiectasia |
1 | hereditary benign telangiectasia |
1 | heart failure |
1 | health status |
1 | head drops |
1 | habitat distribution |
1 | h, Hour |
1 | guidelines |
1 | glycolysis |
1 | glutamate antagonists |
1 | globus pallidus internus |
1 | genotype |
1 | genome‐wide association |
1 | gene‐environment interaction |
1 | gene‐disease associations |
1 | gamma-Aminobutyric Acid (metabolism) |
1 | galaxies: statistics |
1 | galaxies: individual: NGC 1275 |
1 | galaxies: clusters: general |
1 | g, Gram |
1 | functional magnetic resonance imaging |
1 | frontotemporal dementia with parkinsonism linked to chromosome 17 |
1 | frog |
1 | fragile X syndrome |
1 | focal cortical dysplasia |
1 | fluorescent probes |
1 | fishery management |
1 | fishery effects |
1 | fisheries management |
1 | fish schools |
1 | fetal pads |
1 | falling |
1 | facial |
1 | executive functions |
1 | ethics |
1 | electrostatic surface analysis |
1 | efficacy |
1 | effective distance |
1 | ecophysiology |
1 | dyskinesias |
1 | dural venous sinuses |
1 | drug efflux transporters |
1 | dopamine |
1 | disease transmission |
1 | dioxins |
1 | dinoflagellate cyst |
1 | dibenzofurans |
1 | diagnosis |
1 | depression |
1 | dementia |
1 | databases |
1 | database schema |
1 | data model |
1 | dark matter |
1 | dark ages, reionization, first stars |
1 | d-amphetamine |
1 | cruelty |
1 | cosmology: observations |
1 | cosmological parameters |
1 | corticobasal degeneration |
1 | coprolalia |
1 | congenital Chiari I malformation |